VANI
Get informed when a big investor buys or sells
+ FollowOvervalued by 103.2% based on the discounted cash flow analysis.
| Market cap | $110.38 Million |
|---|---|
| Enterprise Value | $108.91 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.43 |
| Beta | 3.29 |
| Outstanding Shares | 81,269,000 |
| P/E Ratio | -3.2 |
|---|---|
| PEG | -42.19 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.91 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 0.96 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 24.55% |
|---|---|
| Total Calls | 14,100▼ 68.53% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 6.90%▼ 1.85% |
|---|---|
| Total Invested | $5.61M▼ 16.46% |
| Investors Holding | 44▲ 7.00% |
No data
Second Sight Medical Products, Inc. (NASDAQ: EYES) develops, manufactures and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulatio...